Longeveron Inc LGVN
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-02-12 |
| Shares Out. | 31,600,000 |
| Website | longeveron.com/ ↗ |
| Phone | 13053027158 |
| Employees | 38 |
| Revenue | $398,000 |
| Gross Profit | $264,000 |
| Net Income | -$4.7M |
| Free Cash Flow | -$18.5M |
| Total Assets | $21.2M |
| Total Liabilities | $5.2M |
| Equity | $16.0M |
About Longeveron Inc
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Longeveron Inc is a publicly traded company under the ticker symbol LGVN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)